Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry

Li,Jing; Yang,Guang-Zhi; Zhu,Zi-Man; Zhou,Zhi-Yong; Li,Lin

doi:10.3892/etm.2012.465

Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry

Authors:
- Jing Li
- Guang-Zhi Yang
- Zi-Man Zhu
- Zhi-Yong Zhou
- Lin Li
View Affiliations

Affiliations: Department of Pathology, the General Hospital of Beijing Military Command, Beijing 100700, P.R. China, Department of Surgery, The 304th Hospital of PLA, Beijing 100037, P.R. China, Department of Gastroenterology, The 306th Hospital of PLA, Beijing 100101, P.R. China
Published online on: January 30, 2012 https://doi.org/10.3892/etm.2012.465
Pages: 621-624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteopontin (OPN), a secreted phosphorylated glycoprotein, has been found to be involved in carcinogenesis, progression and metastasis of several types of cancers. The aim of the present study was to investigate the immunohistochemical expression of OPN in colorectal carcinoma (CRC) and its relationship with clinicopathological parameters and P53. Expression of OPN, Ki-67 and TP53 was detected in 77 cases of CRC by immunohistochemistry and the correlation of the expression of OPN with clinicopathological features, Ki-67 and P53 staining was investigated. Thirty-eight cases (49.4%) of CRC demonstrated OPN overexpression. Overexpression of OPN was associated with lymph node metastasis (P=0.025) and Dukes' stages (P=0.031), but not with gender, histological differentiation, depth of tumor invasion, TNM stages or Ki-67 index. The correlation between expression of OPN and TP53 was statistically significant (P=0.030). In conclusion, OPN is overexpressed in CRC, and plays a role in tumor progression and metastasis, which is possibly regulated by P53.

View Figures

View References

1.	Denhardt DT and Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 30–31:92–102. 1998.PubMed/NCBI
2.	Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J. 7:1475–1482. 1993.PubMed/NCBI
3.	Lund SA, Giachelli CM and Scatena M: The role of osteopontin in inflammatory processes. J Cell Commun Signal. 3:311–322. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Patani N, Jouhra F, Jiang W and Mokbel K: Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 28:4105–4110. 2008.PubMed/NCBI
5.	Higashiyama M, Ito T, Tanaka E and Shimada Y: Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 14:3419–3127. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 103:861–869. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y and Hatakeyama K: Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol. 39:1777–1783. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 94:513–521. 2002. View Article : Google Scholar
10.	Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR and Janssen KP: Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 21:1717–1723. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 169:233–246. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegård D and Andersson G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis. 20:437–444. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Irby RB, McCarthy SM and Yeatman TJ: Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis. 21:515–523. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 27:103–118. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Leali D, Moroni E, Bussolino F and Presta M: Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. J Biol Chem. 282:19676–19684. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Anborgh PH, Mutrie JC, Tuck AB and Chambers AF: Role of the metastasis-promoting protein osteopontin in the tumour micro-environment. J Cell Mol Med. 14:2037–2044. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS and Lu PJ: Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation. Ann Surg Oncol. 17:3043–3052. 2010. View Article : Google Scholar
18.	Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W and Guo Y: Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 28:3412–3422. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY and Tang CH: Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer. 64:263–270. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Tuck AB, Hota C and Chambers AF: Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat. 70:197–204. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S and Yamamoto S: Cloning and characterization of the human osteopontin gene and its promoter. Biochem J. 303:255–262. 1994.PubMed/NCBI
22.	Morimoto I, Sasaki Y, Ishida S, Imai K and Tokino T: Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer. 33:270–278. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A and Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers. 25:164–170. 2010.
24.	Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS, Chandramouli BA, et al: Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev. 19:1409–1422. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K and Mack PC: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 4:1104–1110. 2009. View Article : Google Scholar : PubMed/NCBI